TR199900648T2 - Lipid d�zeylerini d���rmek i�in sibutramin analoglar�n�n kullan�m�. - Google Patents
Lipid d�zeylerini d���rmek i�in sibutramin analoglar�n�n kullan�m�.Info
- Publication number
- TR199900648T2 TR199900648T2 TR1999/00648T TR9900648T TR199900648T2 TR 199900648 T2 TR199900648 T2 TR 199900648T2 TR 1999/00648 T TR1999/00648 T TR 1999/00648T TR 9900648 T TR9900648 T TR 9900648T TR 199900648 T2 TR199900648 T2 TR 199900648T2
- Authority
- TR
- Turkey
- Prior art keywords
- zeylerini
- rmek
- kullan
- analoglar
- sibutramin
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 2
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Fats And Perfumes (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Analogue/Digital Conversion (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619961.7A GB9619961D0 (en) | 1996-09-25 | 1996-09-25 | Medical treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR199900648T2 true TR199900648T2 (xx) | 1999-06-21 |
Family
ID=10800447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR1999/00648T TR199900648T2 (xx) | 1996-09-25 | 1997-09-15 | Lipid d�zeylerini d���rmek i�in sibutramin analoglar�n�n kullan�m�. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6187820B1 (https=) |
| EP (1) | EP0973511B1 (https=) |
| JP (1) | JP4143126B2 (https=) |
| KR (1) | KR100573333B1 (https=) |
| CN (1) | CN1173696C (https=) |
| AT (1) | ATE239459T1 (https=) |
| AU (1) | AU724645B2 (https=) |
| BG (1) | BG64472B1 (https=) |
| BR (1) | BR9711411A (https=) |
| CA (1) | CA2266378C (https=) |
| CZ (1) | CZ291879B6 (https=) |
| DE (1) | DE69721833T2 (https=) |
| DK (1) | DK0973511T3 (https=) |
| ES (1) | ES2199354T3 (https=) |
| GB (1) | GB9619961D0 (https=) |
| HU (1) | HU224711B1 (https=) |
| IL (1) | IL128820A (https=) |
| NO (1) | NO991424D0 (https=) |
| NZ (1) | NZ334550A (https=) |
| PL (1) | PL190017B1 (https=) |
| PT (1) | PT973511E (https=) |
| RU (1) | RU2197959C2 (https=) |
| SK (1) | SK284282B6 (https=) |
| TR (1) | TR199900648T2 (https=) |
| UA (1) | UA63916C2 (https=) |
| WO (1) | WO1998013034A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974838B2 (en) | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
| US6476078B2 (en) | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
| AU2007200334B8 (en) * | 1998-08-24 | 2010-10-21 | Sepracor, Inc. | Methods of using and compositions comprising dopamine reuptake inhibitors |
| US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6046242A (en) * | 1998-11-27 | 2000-04-04 | Basf Aktiengesellschaft | Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence |
| US6696495B2 (en) | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
| US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
| US6552087B1 (en) | 1999-03-19 | 2003-04-22 | Abbott Gmbh & Co. Kg | Therapeutic agent comprising (+)-sibutramine |
| AU3894500A (en) * | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Prevention of cardiovascular disease |
| US6399826B1 (en) | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
| FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| US6610887B2 (en) | 2001-04-13 | 2003-08-26 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
| JP4278652B2 (ja) * | 2002-10-05 | 2009-06-17 | ハンミ ファーム． シーオー．， エルティーディー． | 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物 |
| EP1622600A1 (en) * | 2003-04-28 | 2006-02-08 | Cipla Ltd. | Pharmaceutical formulation comprising anti-obesity agent and acidulant |
| US20050032908A1 (en) * | 2003-08-04 | 2005-02-10 | Beckman Kristen M. | Methods for treating metabolic syndrome |
| US20050131074A1 (en) * | 2003-08-04 | 2005-06-16 | Beckman Kristen M. | Methods for treating metabolic syndrome |
| KR100618176B1 (ko) | 2004-12-02 | 2006-09-01 | 휴먼팜 주식회사 | 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물 |
| KR20060080817A (ko) | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 디카복실산염 |
| WO2006073292A1 (en) * | 2005-01-06 | 2006-07-13 | Cj Corporation | Inorganic acid salts of sibutramine |
| KR20060080818A (ko) * | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 술폰산염 |
| KR20060093564A (ko) * | 2005-02-22 | 2006-08-25 | 종근당바이오 주식회사 | 무수 시부트라민 말산염 및 이의 제조 방법 |
| KR100627687B1 (ko) * | 2005-04-20 | 2006-09-25 | 주식회사 씨티씨바이오 | 시부트라민 유리염기 함유 조성물 및 이의 제조방법 |
| KR100814384B1 (ko) * | 2006-02-10 | 2008-03-18 | 대화제약 주식회사 | 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법 |
| WO2008034142A2 (en) | 2006-09-15 | 2008-03-20 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cycloalkylmethylamines |
| US8604244B2 (en) | 2010-07-02 | 2013-12-10 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
| KR20080046601A (ko) * | 2006-11-22 | 2008-05-27 | 에스케이케미칼주식회사 | 보관안정성이 우수한 시부트라민 함유 포접복합체 |
| WO2010082216A2 (en) * | 2008-12-08 | 2010-07-22 | Matrix Laboratories Ltd | Novel salts of sibutramine and their crystal forms |
| RU2642074C2 (ru) | 2011-12-30 | 2018-01-24 | Ревива Фармасьютикалс, Инк. | Композиции, синтез и способы применения производных фенилциклоалкилметиламина |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52768B1 (en) | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
| GB8531071D0 (en) * | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| GB8704777D0 (en) * | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
| JP2675573B2 (ja) * | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
| IE61928B1 (en) * | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| US5459164A (en) * | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
-
1996
- 1996-09-25 GB GBGB9619961.7A patent/GB9619961D0/en active Pending
-
1997
- 1997-09-15 SK SK320-99A patent/SK284282B6/sk unknown
- 1997-09-15 DE DE69721833T patent/DE69721833T2/de not_active Expired - Lifetime
- 1997-09-15 CZ CZ1999932A patent/CZ291879B6/cs not_active IP Right Cessation
- 1997-09-15 CA CA002266378A patent/CA2266378C/en not_active Expired - Fee Related
- 1997-09-15 RU RU99108731/14A patent/RU2197959C2/ru active
- 1997-09-15 TR TR1999/00648T patent/TR199900648T2/xx unknown
- 1997-09-15 ES ES97910289T patent/ES2199354T3/es not_active Expired - Lifetime
- 1997-09-15 JP JP51521998A patent/JP4143126B2/ja not_active Expired - Fee Related
- 1997-09-15 CN CNB971982341A patent/CN1173696C/zh not_active Expired - Fee Related
- 1997-09-15 PL PL97332367A patent/PL190017B1/pl not_active IP Right Cessation
- 1997-09-15 AU AU47741/97A patent/AU724645B2/en not_active Ceased
- 1997-09-15 US US09/269,340 patent/US6187820B1/en not_active Expired - Lifetime
- 1997-09-15 EP EP97910289A patent/EP0973511B1/en not_active Expired - Lifetime
- 1997-09-15 IL IL12882097A patent/IL128820A/en not_active IP Right Cessation
- 1997-09-15 NZ NZ334550A patent/NZ334550A/xx not_active IP Right Cessation
- 1997-09-15 KR KR1019997002490A patent/KR100573333B1/ko not_active Expired - Fee Related
- 1997-09-15 UA UA99042290A patent/UA63916C2/uk unknown
- 1997-09-15 WO PCT/EP1997/005040 patent/WO1998013034A1/en not_active Ceased
- 1997-09-15 HU HU9903823A patent/HU224711B1/hu active IP Right Grant
- 1997-09-15 DK DK97910289T patent/DK0973511T3/da active
- 1997-09-15 BR BR9711411A patent/BR9711411A/pt not_active IP Right Cessation
- 1997-09-15 AT AT97910289T patent/ATE239459T1/de not_active IP Right Cessation
- 1997-09-15 PT PT97910289T patent/PT973511E/pt unknown
-
1999
- 1999-03-15 BG BG103249A patent/BG64472B1/bg unknown
- 1999-03-24 NO NO991424A patent/NO991424D0/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199900648T2 (xx) | Lipid d�zeylerini d���rmek i�in sibutramin analoglar�n�n kullan�m�. | |
| TW347387B (en) | Piperidine derivatives | |
| TW336939B (en) | Lipopeptide derivatives, a process for their preparation and their use | |
| ES2160640T3 (es) | Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos. | |
| IL116122A0 (en) | Intermediates to heterocyclic-cyclic amine derivatives | |
| DK0763031T3 (da) | Piperazinderivater | |
| GR3033269T3 (en) | Methods of inhibiting viral replication | |
| MX9701325A (es) | Metodos para inhibir la mucositis ulcerativa. | |
| KR960007592A (ko) | 신규한 피롤로카바졸 | |
| LU92263I2 (fr) | Imépitoïne et ses dérivés pharmaceutiquement acceptables (PEXION) | |
| NO20001515L (no) | Vitronektin reseptor-antagonist | |
| NO891949D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive pyrimidindionforbindelser. | |
| ATE282608T1 (de) | Chinoxalindionen | |
| EA199900684A1 (ru) | Производные иминоазаантрациклинона для лечения амилоидоза | |
| ATE63309T1 (de) | 2,3-dihydro-2-oxo-3-benzofuranylessigs|urederivate und diese enthaltende arzneimittel. | |
| CO5140085A1 (es) | Derivados terapeuticos de benzamida | |
| GB2135997B (en) | N-(m-trifluoromethylphenyl)-n'-propargylpiperazine | |
| DK0771201T3 (da) | Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et medikament til inhibering af primær endometrisk hyperplasi | |
| MX9605794A (es) | Intermediario para preparar un compuesto farmaceuticamente activo. | |
| TR200102700T2 (tr) | Karın fıtığının (hiatal hernia) tedavisi. | |
| TR200102694T2 (tr) | Hamilelik sonrası kilo kaybı. | |
| CO5271685A1 (es) | Profarmacos de compuestos de triazol y un grupo 2,4-difluorofenilo, composiciones farmaceuticas que los contienen y procedimiento de obtencion de los mismos | |
| GT199400081A (es) | Procedimiento para la preparacion de derivados de acidos 1- (2-fluorciclopropil)-quinolon y naftiridon carboxilicos |